Journal of Medical Economics

Article	Citations
Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada	91
Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible	56
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	48
The economic burden of systemic lupus erythematosus in Taiwan	47
Socioeconomic effects of establishing a new stroke center in Central Switzerland	36
Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia	32
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait	27
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK	27
Real-world clinical management of individuals with Rett syndrome: a physician survey	27
The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs	26
Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program	25
Improved hospital discharge and cost savings with esophageal cooling during left atrial ablation	24
Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Sa	24
Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific	23
Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategy	23
The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis	22
Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective	20
Racial variation in healthcare resource utilization and expenditures in knee/hip osteoarthritis patients: a retrospective analysis of a Medicaid population	19
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden	19
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States	17
Ten-year cost-consequence analysis of weight loss on obesity-related outcomes in privately insured adults with obesity in Saudi Arabia	16
Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment	15
Early exploration of the economic impact of transradial access (TRA) versus transfemoral access (TFA) for neurovascular procedures in Spain	14
The economic burden of systemic lupus erythematosus in Mexico	14
Value of next generation sequencing (NGS) testing in advanced cancer patients	14

Cost-effectiveness analysis of transcatheter aortic valve implantation in aortic stenosis patients at low- and intermediate-surgical risk in Japan	13
Cost-effectiveness analysis of a lung cancer screening program in the Netherlands: a simulation based on NELSON and NLST study outcomes	13
Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis	13
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	12
Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis	12
Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China	12
Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United States	11
Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs	11
Long-run savings associated with surgical aortic valve replacement using a RESILIA tissue bioprosthetic valve versus a mechanical valve	11
QALYs and ambulatory status: societal preferences for healthcare decision making	10
Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease	10
Moving preinduction cervical ripening to a lower acuity inpatient setting using the synthetic hygroscopic cervical dilator: a cost-consequence analysis for the United States	10
Journal of Medical Economics in review: the best of 2021	10
Clinical and economic burden of HPV-related cancers in the US veteran population	10
Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States	10
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	9
Global article collection: essential reads from around the world	9
A discrete choice experiment investigating HIV testing preferences in South Africa	9
Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population	9
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	9
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evalu	9
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	9
Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in	9
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system persp	8
Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs	8
Correction	8
A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service	8
Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis	8
Clinical and economic benefits of patients undergoing lobectomy with the use of powered vascular staplers—based on China’s real-world data	8
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	8
A breath of fresh AIR: reducing the carbon footprint of asthma	8
Correction	8
A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia	7
Value-based pricing: a potential solution to difficult pricing discussions and payers’ negotiations	7
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the Unit	7
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	7
Addendum	7
Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study	7
Critical appraisal on “Assessing the cost-effectiveness of once-weekly somatrogon vs. daily somatropin for pediatric growth hormone deficiency”	7
Addendum	7
Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression	7
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type	6
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	6
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia	6
Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab	6
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	6
Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages	6
Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia	6
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population	6
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England	6

Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada	6
Relationship between a diagnosis of kidney failure and heart diseases in patients with hyperkalemia	6
Prevalence, incidence, patient characteristics, and treatment trends of valvular heart disease using the national database of health insurance claims of Japan	6
Asian innovation in pharmaceutical and medical device industry – beyond tomorrow	6
Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain	5
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States	5
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany	5
Burden and indirect cost of vaccine-preventable cancer mortality in Europe	5
Budget impact analysis of a bioprosthetic valve with a novel tissue versus mechanical aortic valve replacement in patients older than 65 years with aortic stenosis in Saudi Arabia	5
Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis	5
Clinical and economic burden of systemic lupus erythematosus in Colombia	5
How AI is advancing asthma management? Insights into economic and clinical aspects	5
Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan	5
Implementation of technology in healthcare entities – barriers and success factors	5
Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer	5
Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza	5
Beyond medicines’ barriers: exploring the true cost of multiple myeloma	5
Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt	5
Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs	5
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	5
Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019	5
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China	5
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States	5
Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation	5
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis	5
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings	4
Cost impact analysis of novel host-response diagnostic for patients with community-acquired pneumonia in the emergency department	4
Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study	4
Emergent challenges and opportunities in drug discovery and commercialization	4
Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease	4
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation	4
DCE attribute development investigating public policy for the provision of medicinal cannabis	4
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States	4
All-cause claims analysis of the LATERA absorbable nasal implant vs surgical repair in patients with nasal valve collapse	4
Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan	4
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective	4
Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors	4
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland	4
Exclusive human milk diet: a challenging innovation in neonatal care	4
Reply letter to “Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal”	4
Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach	4
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis	4
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid or	4
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States	4
Healthcare resource utilization and costs for patients with postoperative atrial fibrillation in the United States	4
Estimation of the cost of influenza antiviral medication guidance or support provided by healthcare professionals: a questionnaire survey in Japan	4
Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis	4
Health state utilities associated with weight loss in type 2 diabetes and obesity	4
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare	4
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm	4
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	4
Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19	4
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital	4
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States	4
Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France	4
Consequences of India’s population aging to its healthcare financing and provision	4
Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation	4
A pragmatic review of cost-effectiveness evaluations of reimbursed medical devices conducted for Japan	3
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States	3
Applications of AI in pharmacy practice: a look at hospital and community settings	3
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan	3
Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention	3
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States	3
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	3
Economic review of point-of-care EEG	3
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)	3
Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder	3
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	3
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	3
Cost-effectiveness of tezepelumab in Canada for severe asthma	3
Analysis of factors associated with premiums for reimbursed medical devices in Japan	3
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective	3
Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s Disease (aPD): demonstration of savings from a societal perspective in the UK	3
Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis	3
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	3
Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study	3
Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysis	3
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	3
Vaccine preparation time, errors, satisfaction, and preference of prefilled syringes versus RSV vaccines requiring reconstitution: randomized, time and motion study	3
The impact of vaccination and outpatient treatment on the economic burden of Covid-19 in the United States omicron era: a systematic literature review	3

Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	3
U.S. payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early-stage invasive breast cancer	3
Cost-of-illness analysis of Chronic Kidney Disease (CKD) management in the Philippines	3
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden	3
Utilities associated with stoma-related complications: peristomal skin complications and leakages	3
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent n	3
Cost-effectiveness of a novel urethral catheter safety device in preventing catheterization injuries in the UK	3
Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis	3
Challenges in health economics research: insights from real-world examples	3
Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan	3
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer	3
Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries	3
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children	3
Estimating hospitalization costs for Health Technology Appraisals (HTA) in England: a systematic literature review and best practice framework	3
The Global South political economy of health financing and spending landscape – history and presence	3
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population	3
Characterizing attributes of innovation of technologies for healthcare: a systematic review	3
The economic burden of Ebola virus disease: a review and recommendations for analysis	3
Placebo responses vary by route of administration in migraine prevention trials. What does this mean?	3